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Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4
and PD-1 have reinvigorated the field of cancer immunotherapy.These agents have demon-
strated clinical activity across a variety of tumor types. Now that safety and clinical activity
has been demonstrated in the monotherapy setting, the field is moving in the direction of
testing novel combinations.
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INTRODUCTION
Immunotherapy is poised to assume a more central role in the
treatment of a variety of cancer types. The FDA-approval of the
CTLA-4 blocking antibody, ipilimumab (Bristol-Myers Squibb),
and the PD-1 blocking antibody, pembrolizumab (Merck) in the
treatment of advanced melanoma appear to represent the prover-
bial tip of the iceberg. Accumulating clinical evidence points
toward a promising role for checkpoint blocking antibodies in
a rapidly expanding spectrum of additional solid tumors includ-
ing non-small cell lung cancer, renal cell cancer, ovarian cancer,
bladder cancer, head and neck cancer, and gastric cancer. While
single agent CTLA-4 or PD-1 pathway blockade has demonstrated
clear anti-tumor activity across multiple tumor types, responding
patients are still in the minority, underscoring the importance of
improving upon present options. Furthermore, in some tumors
types, such as prostate cancer, single agents have a low level of
activity that may be improved upon with combination approaches.
Combined checkpoint blockade, to date explored with CTLA-4
and PD-1 pathway blocking agents, represents a first step in this
new direction. Herein, we shall review the most up to date clin-
ical data on these combinations, discussing both the promising
clinical activity and the increased burden of toxicity seen in such
combinations.
BACKGROUND
This story begins with the success of translating the basic immuno-
logic observation that CTLA-4 is a negative regulator of T cells
into the preclinical observation that blockade of CTLA-4 can have
potent anti-tumor activity in mouse models, and then into the
subsequent clinical trials that tested this concept in a population
of patients with advanced melanoma (1–7). Two phase 3 studies
have demonstrated that the human CTLA-4 blocking antibody,
ipilimumab, offers a benefit in overall survival for patients with
advanced melanoma, leading to the FDA-approval of ipilimumab
in March 2011 (Table 1) (8, 9).
Likewise, for PD-1, a firm foundation of basic immunologic
studies, including mouse models of chronic infectious disease,
helped characterize PD-1 along with its ligands PD-L1 and PD-L2,
as negative regulators of effector T cell function that act predomi-
nantly in the tissue where the immune response in ongoing (10).
Building upon the concept of PD-1 as a negative regulator of T
cell function, subsequent studies demonstrated the potential for
the PD-1 pathway to impact anti-tumor immune responses in a
variety of mouse models of transplantable tumors. These studies
supported the clinical development of agents that interrupt the
PD-1 pathway via blockade of PD-1 itself, or one of its ligands,
PD-L1. At present, numerous agents are being tested in dozens
of clinical trials. At least two PD-1 blocking antibodies, pem-
brolizumab and nivolumab (Bristol-Myers Squibb) have demon-
strated clinical activity in melanoma (Table 1), as well as several
additional solid tumors including non-small cell lung cancer, renal
cell cancer, ovarian cancer, and head and neck cancers (11–21).
Pembrolizumab was approved by the FDA for previously treated
advanced melanoma in September 2014. Three additional PD-L1
blocking antibodies have also shown clinical activity in a vari-
ety of solid tumor types: MEDI4736 (Medimmune), MPDL3280a
(Genentech), and MDX-1105 (Bristol-Myers Squibb) (22–27).
Strong preclinical rationale for the clinical evaluation of com-
bined CTLA-4 and PD-1 pathway blockade was provided by
basic immunologic observations, which supported the notion that
CTLA-4 and PD-1 are non-redundant pathways for the regulation
of T cell responses, suggesting that the combination could have
additive or synergistic potential. Furthermore, two early studies in
mouse models of transplantable syngeneic tumors created further
enthusiasm for this combination. The first study, presented by
Korman and colleagues, demonstrated that the combination of
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Table 1 | Selected clinical trials of CTLA-4 and PD-1 pathway blocking antibodies in advanced melanoma.
Agent tested Patients Treatment arms Response ratesa Survival
CTLA-4 BLOCKADE
Ipilimumab (8) 676 patients with previously treated
advanced melanoma
Ipilimumab vs. gp100 peptide
vaccine vs. combination
Ipilimumab alone: ORR
10.9%
Ipilimumab alone: median
OS: 10.1 months
45.6% at 1 year
23.5% at 2 years
Ipilimumab dosed at 3 mg/kg
every 3 weeks×4 doses
Gp100 vaccine: ORR
1.5%
Gp100 vaccine: Median OS:
6.4 months
25.3% at 1 year
13.7% at 2 years
PD-1 BLOCKADE
Pembrolizumab (21) 173 patients with advanced
melanoma whose disease had
progressed after ipilimumab
Pembrolizumab 2 mg/kg every
3 weeks vs. pembrolizumab
10 mg/kg every 3 weeks
For total study
population: ORR 26%
2 mg/kg dose: 58% at 1 year
10 mg/kg dose: 63% at
1 year
Nivolumab (20) 418 Treatment naive patients with
BRAF wild-type advanced
melanoma
Nivolumab 3 mg/kg every
2 weeks vs. dacarbazine
Nivolumab: ORR: 40% Nivolumab: median OS: NR
72.9% at 1 year
Dacarbazine: ORR:
13.9%
Dacarbazine: median OS:
10.8 months
42.1% at 1 year
COMBINATION
Ipilimumab+nivolumab
(30, 31)
52 patients with advanced
melanoma (cohorts 1, 2, 2A, 3)
Multiple dose cohorts:
ipilimumab
1–3 mg/kg+nivolumab
0.3–3 mg/kg
Across all dose levels:
ORR: 40% (21–53%)
Across all dose levels:
median OS: NR
85% at 1 year
79% at 2 years
NR, not reached; OS, overall survival; ORR, objective response rate.
aThe Hodi et al. andWolchok et al. studies used mWHO to measure response, other studies listed used RECIST criteria.
PD-1 and CTLA-4 blockade had synergistic anti-tumor activity in
a mouse model of colon adenocarcinoma, MC38 (28). In a sub-
sequent article by Curran et al., the authors confirmed the potent
anti-tumor activity of this combination when used with a cellular
vaccine (Gvax or Fvax) in the B16 murine model of melanoma
(29). Additionally, they found that the activity of this triple com-
bination was associated with an increase in effector T cells in the
tumor microenvironment and a relative reduction in the frequency
of regulatory T cells.
COMBINED PD-1 AND CTLA-4 PATHWAY INHIBITION IN
ADVANCED MELANOMA
STUDY DESIGN AND DEMOGRAPHICS
The first study of combined checkpoint blockade tested the com-
bination of ipilimumab with nivolumab in the treatment of
advanced melanoma (Table 1) (30, 31). This small phase 1 dose-
escalation study was designed to test the safety of the combina-
tion of ipilimumab at a dose of 3 mg/kg in combination with
nivolumab at doses ranging from 0.3 to 3 mg/kg (cohorts 1–3).
An exploratory cohort of ipilimumab dosed at 1 mg/kg in com-
bination with nivolumab at 3 mg/kg was also included (cohort
2A). Dose limiting toxicities identified at the dose level of 3 mg/kg
for both drugs identified the maximum tolerated dose for this
combination. Additionally, two cohorts (6 and 7) allowed patients
who had previously received commercial ipilimumab to receive
nivolumab monotherapy as part of the study. Initial data on
safety and response rates for this study were published in 2013
(30). Updated data on the long-term survival for the initial treat-
ment cohorts as well as response rates and safety in an expanded
number of patients treated on study (cohort 8) were reported at
ASCO in 2014 (31). All of the patients treated in cohorts 1–3 and
2A were scheduled to receive concomitant doses ipilimumab and
nivolumab every 3 weeks for a total of 4 doses and eligible patients
who continued on treatment received the combination of both
drugs every 3 months thereafter for up to 2 years. The patients
treated in cohort 8 received ipilimumab at a dose of 3 mg/kg
and nivolumab at a dose of 1 mg/kg. As in cohorts 1–3, patients
were scheduled to receive concomitant doses of ipilimumab and
nivolumab every 3 weeks for a total of 4 doses; however, subse-
quent dosing was on a different schedule where eligible patients
who continued on treatment received nivolumab alone at a dose
of 3 mg/kg every 2 weeks for up to 2 years.
CLINICAL ACTIVITY
The initial report of activity for the concomitant combination of
ipilimumab and nivolumab was notable for objective response rate
(ORR), averaging 40% (ranging from 21 to 53%,n= 52) across all
dose-levels tested (cohorts 1–3, 2A). The inclusion of patients with
stable disease for at least 24 weeks along with responders, defined
as aggregate clinical activity rate, was 65% (50–83%) across all dose
levels. While cross-study comparisons are inherently limited, pre-
viously reported response rates for ipilimumab monotherapy and
nivolumab monotherapy were 11 and 31%, respectively (8, 11, 32).
One notable feature of the responses seen for patients treated with
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the combination was the relatively high rate of complete responses
or near complete responses; 31% of the patients treated with the
concomitant combination had a reduction in disease burden of
80% or greater. Based upon this initial activity, the study was
expanded and an additional 41 patients treated with the concomi-
tant combination of ipilimumab and nivolumab (cohort 8) were
reported upon at ASCO in 2014. In cohort 8, the ORR was 43 with
31% of patients showing a reduction in disease burden of 80% or
greater.
As in prior studies of checkpoint blocking antibodies, the dura-
bility of responses was a notable virtue of this combination. As of
reporting for ASCO 2014, responses were ongoing for the majority
of responding patient and the median duration of response across
all combination cohorts had not been reached. Additionally, sur-
vival data from cohorts 1–3 and 2A were presented at ASCO 2014.
In aggregate, across all cohorts, the 1-year and 2-year survival was
85 and 79%,respectively. In cohort 2, the 1-year and 2-year survival
was 94 and 88%, respectively.
In cohorts 6 and 7, patients who had previously been treated
with ipilimumab as a monotherapy were permitted to be enrolled
to receive nivolumab monotherapy at a dose of either 1 or 3 mg/kg
within a 4–12 weeks window after the last dose of ipilimumab.
While this was not a study requirement, the majority of patients
enrolled in cohorts 6 and 7 had progressive disease after ipili-
mumab treatment, as assessed by their treating physician. The
ORR in these two sequenced combination cohorts was 31% with
all of these responses showing an 80% or greater reduction in
disease burden. Clearly, some of the patients who did not have
a response to ipilimumab monotherapy were able to respond to
subsequent nivolumab treatment, a finding supported by a sec-
ond independent study sequencing nivolumab after ipilimumab
(33). One interesting observation was generated in a retrospective
analysis of residual plasma levels of ipilimumab. Patients were cat-
egorized as having plasma levels of ipilimumab below or above the
median plasma level of 7.255µg/ml and the ORR seen in those
with low plasma levels (14.3%) vs. high plasma levels (57.1%)
appears to favor patients with higher levels of plasma ipilimumab
who received nivolumab subsequently (31).
SAFETY
Toxicities associated with CTLA-4 or PD-1 pathway blockade have
been well described and include a constellation of tissue-specific
inflammatory events that appear consistent with the known
immune-activating mechanism of action for these agents. These
toxicities have been referred to as immune related adverse events
(irAEs) and may affect any number of organ systems including the
gastrointestinal tract (colitis, diarrhea), the lung (pneumonitis),
the endocrine system (hypophysitis, thyroiditis), the liver (hepati-
tis), the skin (rash, pruritus), and the eye (uveitis) among others. In
rare cases, toxicities may be severe and potentially life threatening
(colitis, pneumonitis); however, in most cases, irAEs are reversible
when managed according to standard algorithms that make use of
immunosuppressive medications such as steroids. In the phase
1 study of the combination of ipilimumab and nivolumab in
advanced melanoma, the dose level of 3 mg/kg ipilimumab plus
3 mg/kg nivolumab was identified as exceeding the acceptable
number of adverse events defined by the protocol. At this dose
level, six patients were treated and three of these patients had
grade 3 or 4 elevations in lipase that persisted for at least 3 weeks
or longer. Also, noted in this cohort was one patient with grade 3/4
elevations in LFTs and one patient with grade 3/4 hypophysitis. All
other dose-levels tested were identified as having acceptable levels
of toxicity.
Two notable observations emerge from the data related to tox-
icity in this study. First, the observed toxicities all fall within the
spectrum of irAEs already described for CTLA-4 or PD-1 pathway
blocking agents; no distinctly new toxicities were described in this
study. Second, the frequency of irAEs and the number of patients
with multiple irAEs was notably higher than previously described
for either monotherapy. Across all dose cohorts, 93% of patients
who received the concomitant combination of ipilimumab and
nivolumab had a treatment related toxicity of any grade and 53%
had a grade 3/4 toxicity attributed to treatment. In the initial report
of cohorts 1–3 and 2A, no treatment related deaths were observed,
but in the expanded study including cohort 8, 1 treatment related
death (multi-organ failure related to colitis) was seen among the
94 patients treated. By comparison, for ipilimumab monotherapy,
irAEs of any grade are observed in ~60% of patients and grade
3/4 irAEs were observed in ~15% or patients (8). For nivolumab
monotherapy, the frequency of irAEs is lower still. Consist with
the high frequency of irAEs, 23% (22/94) of patients treated
with the concomitant combination of ipilimumab and nivolumab
discontinued treatment due to toxicities. Nevertheless, many of
the patients who discontinued treatment had ongoing, durable
responses that extended beyond ongoing treatment.
BIOMARKERS
The search for biomarkers that might help select a patient pop-
ulation most likely to benefit from checkpoint blockade is an
area of ongoing research, but to date, no clinically applicable bio-
marker appropriate for patient selection has been identified. For
PD-1 and PD-L1 blocking antibodies, expression of PD-L1 in the
tumor microenvironment has been intensely studies as a poten-
tial biomarker. In a small study (n= 9) from a single dose phase
1 study of nivolumab, Brahmer et al. reported that 3/4 patients
whose tumor expressed PD-L1 on the cell surface responded to
nivolumab whereas none of the remaining patients that tested
negative for PD-L1 responded to the drug (34). In a subsequent
analysis of a larger population of 42 patients, again, responses were
restricted to those patients (9/25) that tested positive for tumor
PD-L1 expression whereas none of the patients that tested nega-
tive (0/17) responded to nivolumab (11). Numerous subsequent
studies have evaluated the potential for PD-L1 expression in the
tumor microenvironment to predict response to PD-1 or PD-L1
blocking agents. Collectively, the data seen in studies of nivolumab,
pembrolizumab, MEDI4736, and MPDL3280a confirm that PD-
L1 expression is a generally favorable feature associated with a
higher rate of response to PD-1 pathway blockade [reviewed in Ref.
(35)]. However, another clear message also emerges from this data;
some patients who test negative for PD-L1 by the assays presently
in use do respond to PD-1 blocking agents, albeit at a lower rate
than their PD-L1 positive counterparts. Several limitations to these
studies remain to be resolved and explored including a lack of
cross-study assay validation. However, given the present status of
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the development of this biomarker, the lack of negative predictive
value for this assay precludes patient selection at this time.
PD-L1 tumor expression as a potential biomarker was explored
in the present study for patients treated with the concurrent com-
bination of ipilimumab and nivolumab (cohorts 1–3, 2A) and for
those who received nivolumab monotherapy sequenced after prior
ipilimumab (cohorts 6 and 7) (30). For those patients treated in the
sequenced cohorts, the trend for PD-L1 expression followed prior
experience for nivolumab monotherapy; an ORR of 50% (4/8) was
seen in patients that tested PD-L1 positive compared to an ORR of
8% (1/13) for those that were PD-L1 negative. In notable contrast,
for those patients that were treated with the concurrent combi-
nation, the ORR was relatively equivalent between those patients
that were PD-L1 positive (46%, 6/13) and those that tested negative
(41%, 9/22). Thus, pre-treatment PD-L1 tumor expression seems
to have little predictive value in the setting of combination treat-
ment, a finding that appears to be best explained by the relatively
high rate of response to the combination seen in patients with
PD-L1 negative tumors. Of course, testing for PD-L1 expression
in a pre-treatment biopsy sample provides only a single static eval-
uation of PD-L1 expression and fails to capture dynamic changes
in the PD-L1 expression that may accompany these treatments.
Additional studies looking at pharmacodynamic changes in the
peripheral blood after treatment with ipilimumab and nivolumab
demonstrated robust changes in immune activation markers such
as ki67 and ICOS as well as upregulation of checkpoint molecules
PD-1 and CTLA-4 (36). In this small sample size, these pharma-
codynamics changes did not correlate with clinical outcomes, but
additional studies are ongoing exploring changes in peripheral
blood and tumor markers in this setting.
Appropriate caution should be applied to the results of a small,
non-randomized phase 1 study conducted at a small number of
academic sites. The true measure of the relative benefit, and toxic-
ity, of this combination approach will be best established in larger,
randomized studies. These studies are better positioned to address
the outstanding questions of the relative benefits of concomitant
vs. sequential therapies with these agents and will better assess the
relative merits and liabilities of a combination regimen with an
apparently higher toxicity burden. A randomized two-arm phase
2 study comparing the combination to ipilimumab monotherapy
(NCT01927419) and a randomized three-arm phase 3 study com-
paring the combination to either nivolumab monotherapy or ipil-
imumab monotherapy (NCT01844505) have completed accrual
and results are awaited.
COMBINED PD-1 AND CTLA-4 PATHWAY INHIBITION IN
RCC (37)
STUDY DESIGN AND DEMOGRAPHICS
The data reported by Dr. Hammers at the ASCO meeting in June
of 2014 reflect two selected cohorts of a larger study, CA209-016
(NCT01472081) where nivolumab was tested in combination with
TKI’s or ipilimumab for the treatment of metastatic RCC. Dr.
Hammers presented data on the two cohorts involving the com-
bination of ipilimumab and nivolumab, either at the dose levels
of 3 mg/kg nivolumab plus 1 mg/kg ipilimumab (N3+ I1) or at
the dose levels of 1 mg/kg nivolumab plus 3mg/kg ipilimumab
(N1+ I3), with 21 and 23 patients, respectively, in each of these
cohorts. The primary endpoint of the study was safety and the
secondary endpoints were ORR, duration of response, and pro-
gression free survival. In contrast to the previously report study
in melanoma, tumor response was assessed by RECIST v 1.1 cri-
teria and the first tumor assessment was performed at 6 weeks.
The treatment schema was comparable to the schedule utilized
in cohort 8 of the melanoma study; the combination was given
every 3 weeks for up to for doses (so called induction) followed
by nivolumab monotherapy administered every 2 weeks, or a
maintenance phase.
For a relatively small study, the two arms, N3+ I1 and N1+ I3
were relatively balanced, although some differences in prior treat-
ment regimens were noted. For example, 57% of the patients in
the N3+ I1 arm received prior IL-2 therapy, whereas only 26%
of patient in the N1+ I3 arm did. Conversely, prior treatment
with antiangiogenic therapies (65 vs. 48%) and mTOR inhibitor
therapies (30 vs. 24%) was more common in the N1+ I3 arm. In
both arms, ~20% of the patients were treatment naïve when they
entered the study. It is unclear what impact, if any, prior thera-
pies may have had on the clinical activity or toxicity seen in the
nivolumab plus ipilimumab combination.
SAFETY
Both combination arms were found to be safe, and no grade 5 treat-
ment related AEs were reported. Nevertheless, treatment related
toxicities were common in both arms, with 76% (N3+ I1) and
100% (N1+ I3) of patients experiencing a toxicity of any grade.
There was an apparent difference in the frequency of grade 3–4
treatment AEs between the two cohorts with only 29% (n= 6) of
patients in the N3+ I1 cohort experiencing these events compared
to 61% (n= 14) of patients in the N1+ I3 cohort. Similar to the
melanoma experience, asymptomatic laboratory abnormalities
such as elevations in AST, ALT, amylase, and lipase comprised
the largest portion of grade 3–4 events. Grade 3–4 diarrhea was
observed in both the N3+ I1 arm (5%) and the N1+ I3 arm
(13%). No cases of grade 3–4 pneumonitis were observed in this
study at the time of reporting.
CLINICAL ACTIVITY
Significant clinical activity for the combination of nivolumab and
ipilimumab was observed in both cohorts with confirmed ORRs
of 43% (N3+ I1) and 48% (N1+ I3). Most of the responses were
ongoing at the time data were reported, 78% in the N3+ I1 arm
and 82% in the N1+ I3 arm. Likewise progression free survival
was similar between N3+ I1 and N1+ I3 arms, with 24 weeks
PFS at 65 and 64%, respectively. With the important caveat that
cross-study comparisons should be taken as hypothesis generat-
ing, the response rates seen with the combination of ipilimumab
and nivolumab compare favorably to those reported for a phase 2
study of nivolumab as a monotherapy, where response rates of 20,
22, and 20% were seen across dose cohorts of 0.3, 2, and 10 mg/kg,
respectively. An important limitation in this comparison is that
all patients in the phase 2 study were previously treated with 1–3
prior therapies including at least 1 antiangiogenic agent.
BIOMARKERS
The biomarker, tumor PD-L1 was also tested in this small study of
RCC. Very consistent with the experience in melanoma, in patients
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treated with the combination of ipilimumab and nivolumab, PD-
L1 status appears unrelated to response rate. This stands in contrast
to the experience with PD-L1 status in patients treated with PD-1
blockade alone.
COMBINED PD-1 AND CTLA-4 PATHWAY INHIBITION IN
NSCLC (38)
STUDY DESIGN AND DEMOGRAPHICS
The abstract reported by Dr. Antonio at the ASCO meeting in June
of 2014 reflected two selected cohorts of a larger study, CA209-012
(NCT01454102) where nivolumab combinations were tested for
the treatment of squamous or non-squamous advanced NSCLC.
Dr. Antonio presented data on the two cohorts involving the
combination of ipilimumab and nivolumab, either at the dose lev-
els of 3 mg/kg nivolumab plus 1 mg/kg ipilimumab (N3+ I1) or
at the dose levels of 1 mg/kg nivolumab plus 3 mg/kg ipilimumab
(N1+ I3), with 25 (9 squamous, 16 non-squamous) and 24 (9
squamous, 14 non-squamous) patients, respectively, in each these
cohorts. The primary endpoint of the study was safety and tol-
erability and the secondary endpoints were ORR and progression
free survival at 24 weeks. As in the RCC study, tumor response was
assessed by RECIST v 1.1 criteria; the first tumor assessment was
performed at 10 weeks. The treatment schema was comparable to
the schedule utilized in cohort 8 of the melanoma study; the com-
bination was given every 3 weeks for up to for doses (so called
induction) followed by nivolumab monotherapy administered
every 2 weeks, or a maintenance phase.
SAFETY
Treatment related toxicities were common across all arms of
the study with an 88% aggregate rate of toxicities of any grade,
78% in the squamous N1+ I3 arm, 100% in the non-squamous
N1+ I3 arm, 78% in the squamous N3+ I1 arm, and 88% in
the non-squamous N3+ I1 arm. A number of serious, grade 3–4
adverse events were reported including pneumonitis (6%), diar-
rhea/colitis (16%), rash (4%), endocrinopathies (6%) nephritis
(2%), and hepatitis (8%). Three deaths that were due to drug-
related toxicities were reported including 1 case each of respiratory
failure following grade 3 colitis, pulmonary hemorrhage, and toxic
epidermal necrolysis in a patient with a history of colitis.
CLINICAL ACTIVITY
Clinical activity for the combination of nivolumab and ipili-
mumab was relatively modest across cohorts in this small study
of NSCLC, with an aggregate ORR of 16%. Response rates in
each individual arm were 11% (squamous, N1+ I3), 13% (non-
squamous N1+ I3), 33% (squamous, N3+ I1), and 13% (non-
squamous, N3+ I1). PFS at 24 weeks was 41% for patients in the
N1+ I3 arm and 29% for patients in the N3+ I1 arm. As reported
previous in both melanoma and RCC, PD-L1 status appeared to
have no clear predictive value in patients with NSCLC treated with
the combination of ipilimumab and nivolumab.
OUTSTANDING QUESTIONS
The combination of ipilimumab and nivolumab is just the first step
in exploring the utility of combined checkpoint blockade. Further
studies testing this combination in a variety of tumor types are
ongoing. Additional approaches to testing combined CTLA-4 and
PD-1 pathway blockade, including the combination of tremeli-
mumab and MEDI4736 are also underway. As new agents become
available, including checkpoint blocking antibodies against LAG-
3, Tim-3, among other targets, new opportunities for combina-
tions will abound. Despite preclinical data in mouse models, it is
unclear which combinations, in which disease types and at which
doses/schedules will have the greatest impact on human cancers.
We await additional clinical data to guide these choices.
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